Lipids
CV
+4
Aug 15, 2026
•
9 min read
One in Five Carry It. Nothing You Prescribe Touches It.
Lp(a) is the most common inherited cardiovascular risk factor in medicine — and the first outcomes trial that could give us a drug for it has gone quiet.
Lipids
+1
Jul 18, 2026
•
2 min read
The PCSK9 Pill Is Here. The Needle Was the Barrier.
The FDA approved the first oral PCSK9 inhibitor — antibody-class LDL-C lowering from a once-daily tablet. Here is what it does, and the one thing it hasn't proven yet.
CV
+1
Jun 13, 2026
•
7 min read
Zero Calcium. Doubled Plaque.
A new natural-history study watched atherosclerosis grow in untreated, low-risk adults over five years — and quietly made the strongest case I’ve seen in years for treating LDL early and aggressively.
CV
+2
Jun 9, 2026
•
10 min read
The Cholesterol You Were Born With
Lp(a) drives heart attacks, strokes, and aortic stenosis in one in five people. Statins don’t touch it. Diet doesn’t move it. After six decades of therapeutic silence, 2026 is the year the verdict finally arrives — and a single gene edit may make the problem history.
CV
+3
Apr 15, 2026
•
16 min read
Statins Don't Cause What You Think They Cause. Except When They Do.
Muscle damage. Memory loss. Cancer. Diabetes. Four fears, one physician, and what the evidence actually shows.
CV
+3
Apr 11, 2026
•
12 min read
Statins Don't Lower LDL.Your Liver Does.
The receptor story that explains 40 years of cardiovascular outcomes data — and why the pleiotropic hypothesis was never the whole story.
GLP1
+2
Apr 8, 2026
•
14 min read
The Longevity Stack
Six interventions. One thesis about time. What I take every morning and why the evidence earned each one a place in the rotation.
